1
Evidence Synthesis
Student Name
Chamberlain College of Nursing
NR 716: Analytic Methods
Due Date
, 2
Evidence Synthesis
In the United States, nearly 41,260 fresh cases of primary liver cancer will be discovered
in 2022, and the most common liver cancer type is hepatocellular carcinoma (HCC) (American
Cancer Society [ACS], 2022; Trung et al., 2018). However, even with substantial changes and
encroachments in HCC therapy, the outcome for HCC patients remains disappointing, as
recognized at an advanced stage (ACS, 2022; Huang et al., 2020). In addition, a lack of early
diagnosis techniques and poor chemotherapy responses add to HCC's high death rate (ACS,
2022; Centers for Disease Control and Prevention [CDC], 2022; (National Cancer Institute
[NCI], 2022; Zheng et al., 2018). Hence, more screening tests for early HCC discovery are
required. It is decisive in clinical routine to scrutinize and evaluate for early detection of HCC.
Three research studies (Huang et al., 2020; Trung et al., 2018; Zheng et al., 2018) discussed lab
tests to find blood levels of lncRNAs, miRNAs, the serum lncRNA, and urothelial carcinoma
associated 1 (UCA1) that are practical in recognizing patients with HCC, assisting in the
diagnosis, and assisting with clinical practice for patients with early-stage HCC.
This paper aims to perform an evidence synthesis using three single-study quantitative
research articles and three non-research evidence-based sources to evaluate research on current
issues related to the early detection of HCC in combination with imaging studies in high-risk
patients.
Analysis of the Practice Problem
HCC is one of the most aggressive carcinomas and the third major cause of cancer-
related mortality worldwide (CDC, 2022; Huang et al., 2020; Trung et al., 2018; Zheng et al.,
2018). In the United States, roughly 41,260 new cases of primary liver cancer will be detected in
2022, and nearly 30,520 individuals (20,420 men and 10,100 women) will yield to these cancers
Evidence Synthesis
Student Name
Chamberlain College of Nursing
NR 716: Analytic Methods
Due Date
, 2
Evidence Synthesis
In the United States, nearly 41,260 fresh cases of primary liver cancer will be discovered
in 2022, and the most common liver cancer type is hepatocellular carcinoma (HCC) (American
Cancer Society [ACS], 2022; Trung et al., 2018). However, even with substantial changes and
encroachments in HCC therapy, the outcome for HCC patients remains disappointing, as
recognized at an advanced stage (ACS, 2022; Huang et al., 2020). In addition, a lack of early
diagnosis techniques and poor chemotherapy responses add to HCC's high death rate (ACS,
2022; Centers for Disease Control and Prevention [CDC], 2022; (National Cancer Institute
[NCI], 2022; Zheng et al., 2018). Hence, more screening tests for early HCC discovery are
required. It is decisive in clinical routine to scrutinize and evaluate for early detection of HCC.
Three research studies (Huang et al., 2020; Trung et al., 2018; Zheng et al., 2018) discussed lab
tests to find blood levels of lncRNAs, miRNAs, the serum lncRNA, and urothelial carcinoma
associated 1 (UCA1) that are practical in recognizing patients with HCC, assisting in the
diagnosis, and assisting with clinical practice for patients with early-stage HCC.
This paper aims to perform an evidence synthesis using three single-study quantitative
research articles and three non-research evidence-based sources to evaluate research on current
issues related to the early detection of HCC in combination with imaging studies in high-risk
patients.
Analysis of the Practice Problem
HCC is one of the most aggressive carcinomas and the third major cause of cancer-
related mortality worldwide (CDC, 2022; Huang et al., 2020; Trung et al., 2018; Zheng et al.,
2018). In the United States, roughly 41,260 new cases of primary liver cancer will be detected in
2022, and nearly 30,520 individuals (20,420 men and 10,100 women) will yield to these cancers
